ChemicalBook > Product Catalog >Pharmaceutical intermediates >Bulk Drug Intermediates >Tofacitinib citrate

Tofacitinib citrate

Tofacitinib citrate Suppliers list
Company Name:Lanzhou Boc Chemical Co., Ltd  Gold
Company Name:Shanghai Haoyuan Chemexpress Co., Ltd  Gold
Company Name:PharmaBlock Sciences (Nanjing),Inc.   Gold
Tel:400 025 5188
Company Name:Nanjing RT Pharmaceutical Technology CO.LTD  Gold
Company Name:Mascot I.E. Co., Ltd  Gold
Tofacitinib citrate Basic information
Drug forTreatment of rheumatoid arthritis Application
Product Name:Tofacitinib citrate
Synonyms:1-PIPERIDINEPROPANENITRILE, 4-METHYL-3-(METHYL-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YLAMINO)-BETA-OXO-, (3R,4R)-, 2-HYDROXY-1,2,3-PROPANETRICARBOXYLATE (1:1);1-Piperidinepropanenitrile, 4-Methyl-3-(Methyl-7H-pyrrolo[2,3-d]pyriMidin-4-ylaMino)-β-oxo-, (3R,4R)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1);Tofacitinib citrate (CP-690550);Tofacitinib citrate;Tasocitinib citrate;Tasocitinib citric acid s...;Xeljanz;CP-690550 (Tofacitinib citrate)
Product Categories:Inhibitor;Inhibitors
Mol File:540737-29-9.mol
Tofacitinib citrate Structure
Tofacitinib citrate Chemical Properties
storage temp. room temp
Safety Information
MSDS Information
Tofacitinib citrate Usage And Synthesis
Drug forTreatment of rheumatoid arthritisTofacitinib citrate is a king of drugs developed by the US pharmaceutical company Pfizer for treating rheumatoid arthritis , trade name Xeljanz, for the treatment of methotrexate inadequate response or intolerance to severe active rheumatoid arthritis ( RA) in adult patients. This product is a Janus kinase inhibitor, administered twice daily.
November 6, 2012, the US Food and Drug Administration (FDA) and Pfizer jointly announced Tofacitinib citrate is approved for the treatment of methotrexate inadequate response or intolerance to severe active rheumatoid joints arthritis (RA) in adult patients.
Xeljanz can be used as monotherapy or in combination with methotrexate or other non-biological disease-modifying antirheumatic drugs (the DMARD) in combination. This medicine should not be in combination with biological DMARD or strong immunosuppressants (such as cyclosporine and azathioprine) . Xeljanz is approved by the daily dose of 2 times, each time 5mg.
Seven clinical trials evaluated the safety and efficacy of Tofacitinib citrate in moderate to severe active RA in adult patients. In all tests, compared with patients receiving placebo, patients receiving Xeljanz treatment showed significant improvement in clinical response and physical function.
In Clinical trials, the most common adverse events were upper respiratory tract infection, headache, diarrhea, nasal congestion, sore throat, and nasopharyngitis.
Using Xeljanz was associated with an increased risk of serious infections, including opportunistic infections, tuberculosis, cancer and lymphoma. Xeljanz product label attaches boxed warning on these security risks . Xeljanz treatment is also associated with reducing blood cell counts and increasing cholesterol and liver enzyme values.
In order to study Xeljanz long-term impact on heart disease, cancer and severe infections, FDA requires for a post-marketing study, which will evaluate two doses of Xeljanz (Tofacitinib citrate) therapy, and accept a integration of another group of patients approved by the treatment as a control.
The above information is edited by the Chemicalbook of Tian Ye.
ApplicationJak kinase inhibitor, to treat rheumatoid arthritis.
Tropsch erlotinib (477600-75-2) bulk pharmaceutical chemicals.
Tofacitinib citrate Preparation Products And Raw materials
Tag:Tofacitinib citrate(540737-29-9) Related Product Information
Vorinostat Dabrafenib (GSK2118436) Sunitinib Malate Crizotinib N-(3-(5-(4-Chlorophenyl)-1H-pyrrolo[2,3-B]pyridine-3-carbonyl)-2,4-difluorophenyl)propane-1-sulfonaMide Ruxolitinib